Product News: Simple Blood Test Enables More Informed Prostate Cancer Biopsy Decisions

Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry, announced today that it will exhibit its prostate health index (phi) test at the 112th American Urological Association (AUA) Annual Meeting and Exhibition in Boston, Mass., May 13-15, 2017. A simple, multi-analyte blood test, the phi test helps physicians distinguish prostate cancer from benign prostatic conditions in men age 50 years or older with total PSA results in the 4-10 ng/mL range, helping them make more informed biopsy decisions. The FDA-approved test may help to reduce the number of biopsies that are negative for prostate cancer. 

AUA2017 visitors to booth #2247 will discover how the phi test: 

• May reduce unnecessary biopsies and provide more confidence in biopsy decisions*
• Fits into the National Comprehensive Cancer Network (NCCN) recommendations for early detection of prostate cancer
• Offers both health benefits and economic value, as demonstrated in more than 80 published clinical papers and meeting abstracts 

Attendees are also invited to hear renown urology expert, Dr. Massimo Lazzeri, discuss his first-hand experience with the phi test in clinical practice today.

Dates: May 13-14, 2017 

Time: 11:00 a.m. – 1:00 p.m. EST

The phi test is the latest in a portfolio of offerings from Beckman Coulter Diagnostics to help physicians and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. The company’s scalable instruments, comprehensive diagnostic tests and business management services are trusted by clinicians in hospitals, laboratories and other critical care settings around the world.

For more information please visit ProstateHealthIndex.org. To schedule a booth tour, please contact: Betsy Watson - bawatson@beckman.com.